



Published in final edited form as:

Nat Genet. 2015 August ; 47(8): 911–916. doi:10.1038/ng.3341.

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

A full list of authors and affiliations appears at the end of the article.

Introductory Paragraph

Pancreatic cancer is the fourth leading cause of cancer death in the developed world¹. Both inherited high-penetrant mutations in *BRCA2*², *ATM*³, *PALB2*⁴, *BRCA1*⁵, *STK11*⁶, *CDKN2A*⁷ and mismatch repair genes⁸ as well as low-penetrant loci are associated with increased risk^{9–12}. To identify novel loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. Three newly associated regions were identified: 17q25.1 (*LINC00673*, rs11655237, OR=1.26, 95%CI:1.19–1.34, $P=1.42\times 10^{-14}$), 7p13 (*SUGCT*, rs17688601, OR=0.88, 95%CI:0.84–0.92, $P=1.41\times 10^{-8}$), and 3q29 (*TP63*, rs9854771, OR=0.89, 95%CI:0.85–0.93, $P=2.35\times 10^{-8}$). Significant association was detected on 2p13.3 (*ETAA1*, rs1486134, OR=1.14, 95%CI:1.09–1.19, $P=3.36\times 10^{-9}$), a region with prior suggestive evidence in the Han Chinese¹². We replicate previously reported associations at 9q34.2 (*ABO*)⁹, 13q22.1 (*KLF5*)¹⁰, 5p15.33 (*TERT*, *CLPTM1*)^{10,11}, 13q12.2 (*PDX1*)¹¹, 1q32.1 (*NR5A2*)¹⁰, 7q32.3 (*LINC-PINT*)¹¹,

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to: A.P.K (aklein1@jhmi.edu).

⁵⁴These authors contributed equally to this work.

URLs

PanC4: www.panc4.org

GLOBOCAN: globocan.iarc.fr/Default.aspx

PLINK: pngu.mgh.harvard.edu/~purcell/plink/

LIFTOVER: genome.ucsc.edu/cgi-bin/hgLiftOver

SHAPEIT: mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html

IMPUTE2: mathgen.stats.ox.ac.uk/impute/impute_v2.html

SNPTEST: mathgen.stats.ox.ac.uk/genetics_software/snpTEST/snpTEST.html

METAL: csg.sph.umich.edu/abecasis/metal/

HAPLOREG: www.broadinstitute.org/mammals/haploreg/haploreg.php

Author Contributions

D.C, G.M.P, H.A.R, and A.P.K organized and designed the study. F.C and A.P.K organized and supervised the genotyping of samples. E.J.C, E.M, D.C, and A.P.K designed and conducted the statistical analysis. E.J.C, E.M, M.G.G, and A.P.K drafted the first version of the manuscript. P.M.B, S.G, M.G.G, D.L, R.N., S.H.O, G.S, L.T.A, W.R.B, M.F.B, A.B, M.B, P.B, H.B, H.B.B-d-M, F.C, G.C, G.M.C, K.G.C, S.J.C, S.P.C, M.C, L.F, C.F, N.F, M.G, M.H, J.M.H, I.H, E.A.H, R.N.H, R.J.H, V.J, T.J.K, J.K, R.C.K, S.L, L.L, E.M-P, A.M, B.M-D, J.P.N, A.L.O, I.O, C.P, R.P, C.R, A.S, A.S, R.Z.S-S, O.S, F.T, Y.K.V, P.V, B.M.W, H.Y, G.M.P, H.A.R, and A.P.K contributed samples for the GWAS and/or the replication analysis. All authors contributed to the final version of the manuscript.

Competing Financial Interests

Under a licensing agreement between Myriad Genetics, Inc., and the Johns Hopkins University, M. Goggins and A.P. Klein are entitled to a share of royalty received by the University on sales of products related to PALB2. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.

16q23.1(*BCAR1*)¹¹ and 22q12.1 (*ZNRF3*)¹¹. Our study identifies novel loci associated with pancreatic cancer risk.

Main Text

We conducted a two-stage genome-wide association study (GWAS) of pancreatic cancer (Fig. 1). First, genome-wide genotyping of 8052 subjects from nine studies within the Pancreatic Cancer Case-Control Consortium (PanC4) (Supplementary Table 1) was conducted using the HumanOmniExpressExome-8v1 array. The overall study was approved by the Johns Hopkins Institutional Review Board (IRB). Each individual study obtained IRB approval from their parent institution. After quality control (Online Methods, Fig. 1, Supplementary Table 2), 7,956 individuals (4,164 cases and 3,792 controls) and 654,470 SNPs with call rates greater than 98% were analyzed. Unconditional logistic regression analysis adjusted for age and the first seven principal component eigenvectors was conducted under the log-additive genetic model (Fig. 2, Supplementary Fig. 1).

Analysis of 7,956 newly genotyped PanC4 individuals identified a novel locus at 17q25.1 (*LINC00673*, rs7214041, OR=1.38, 95%CI:1.26–1.51, $P=1.95\times 10^{-10}$) significantly associated with pancreatic cancer risk (Table 1, column ‘PanC4’). In addition we replicate regions that had previously been reported to be associated with pancreatic cancer in the Caucasian population (Supplementary Table 3). These include: 9q34.2⁹ (*ABO*, rs505922, OR=1.27, 95%CI:1.19–1.35, $P=1.72\times 10^{-13}$), 13q22.1¹⁰ (*KLF5*, rs9543325, OR=1.24, 95%CI:1.16–1.32, $P=2.26\times 10^{-10}$), 5p15.33¹⁰ (*CLPTM1*, rs401681, OR=1.2, 95% CI:1.13–1.28, $P=2.7\times 10^{-8}$), 13q12.2¹¹ (*PDX1*, rs9581943, OR=1.17, 95%CI:1.10–1.24, $P=1.94\times 10^{-7}$), 1q32.1¹⁰ (*NR5A2*, rs3790844, OR=0.83, 95%CI:0.77–0.90, $P=3.05\times 10^{-6}$), 7q32.3¹¹ (*LINC-PINT*, rs6971499, OR=0.81, 95%CI:0.74–0.88, $P=7.1\times 10^{-6}$), 5p15.33¹¹ (*TERT*, rs2736098, OR=0.85, 95%CI: 0.78–0.93, $P=2.31\times 10^{-5}$), 16q23.1¹¹ (*BCAR1*, rs7190458, OR=1.4, 95%CI=1.22–1.60, $P=1.01\times 10^{-4}$), and 22q12.1¹¹ (*ZNRF3*, rs16986825, OR=1.14, 95% CI= 1.04–1.24, $P=2.72\times 10^{-3}$). In contrast, other than 2p13.3 (*ETAA1*, rs2035565, OR=1.15, 95%CI=1.07–1.25, $P=2.69\times 10^{-4}$) (Supplementary Table 3) we observed no evidence of association ($P>0.05$) for SNPs previously reported to be associated ($P<1\times 10^{-6}$) with pancreatic cancer in Asian populations^{12,13}. While all ethnic groups were included in our analyses, over 92% of our study population reported Caucasian ancestry. We obtained similar results when analysis was limited to individuals reporting European ancestry. Because of limited sample sizes we did not conduct independent analysis of other ethnic groups(results not shown).

We then conducted a genome-wide meta-analysis of the PanC4 data with data from PanScan 1⁹ and PanScan 2¹⁰ (Combined Stage 1, Fig. 1). After quality control (Online Methods and Supplementary Table 4), we analyzed 528,179 SNPs and 3,746 individuals (1,856 cases and 1,890 controls) from PanScan 1 and 557,555 SNPs and 3,300 individuals (1,618 cases and 1,682 controls) from PanScan 2. Since the genotyping platforms differed across studies, missing genotypes were imputed using IMPUTE v2¹⁴, with 1000 Genomes¹⁵ (release Dec 2013) and HapMap3¹⁶ (release #2,2009) as reference panels. For PanScan 1 and PanScan 2, we conducted association analysis using unconditional logistic regression including age and the first four principal components eigenvectors as covariates. Data from PanC4, PanScan 1,

and PanScan 2 were combined (7,638 cases and 7,364 controls and 866,891 SNPs) and analyzed using a fixed-effects model implemented in METAL¹⁷ (Fig. 3). A QQ plot (Supplementary Fig. 2) indicated appropriate control of type-1 errors, with λ values of 1.025 for PanC4, 0.998 for PanScan 1, and 1.017 for PanScan 2.

The Combined Stage 1 Analysis (Table 1, column ‘Combined Stage 1’) yielded a second novel region of association at 3q29 (*TP63*, rs9854771, OR=0.87, 95%CI:0.83–0.92, $P=4.08\times 10^{-8}$). A second SNP on 17q25.1 (rs11655237, OR=1.27, 95%CI:1.19–1.36, $P=6.74\times 10^{-12}$), which is in high LD ($r^2=0.95$) with rs7214041, also gave significant evidence of association in these combined data.

We next conducted a Stage 2 analysis in an independent set of 2,497 cases and 4,611 controls from the PANDoRA consortium¹⁸. We selected twenty-five SNPs from 23 independent regions (Supplementary Table 5) with p-values below 10^{-5} in either PanC4 or the Combined Stage 1 analyses. When multiple SNPs per region were associated, the most significant SNP was selected; SNPs on 17q25.1 and 2p13.3 were exceptions. After quality control (Online Methods, Supplementary Table 6), 2,287 cases and 4,205 controls from the PANDoRA study were analyzed. Age-adjusted association analyses by country were carried out, and results were combined using a fixed-effect model. We observed independent evidence of association at 17q25.1 in the PANDoRA study (Table 1, column ‘PANDoRA’: rs7214041, OR=1.25, 95%CI:1.11–1.41, $P=3.37\times 10^{-4}$).

Combined analysis of the Stage 1 and 2 data for the 25 SNPs (Table 1 and Supplementary Table 5, column ‘Combined Stage 1&2’) revealed two additional significantly associated loci: 2p13.3(*ETAA1*, rs1486134, OR=1.14, 95%CI:1.09–1.19, $P=3.36\times 10^{-9}$) and 7p13(*SUGCT*, rs17688601, OR=0.88, 95%CI:0.84–0.92, $P=1.41\times 10^{-8}$). Promising signals (Supplementary Table 7) arose at 18q21.2(*GRP*, rs1517037, OR=0.87, 95%CI:0.83–0.92, $P=3.17\times 10^{-7}$), 12q24.31(*HNF1A*, rs7310409, OR= 1.11, 95%CI:1.06–1.15, $P=6.34\times 10^{-7}$), 1p13.1(*WNT2B*, rs351365, OR=0.89, 95%CI:0.85–0.93, $P=7.39\times 10^{-7}$), and 20q13.11 (rs6073450, OR=1.11, 95%CI:1.06–1.15, $P=9.21\times 10^{-7}$).

We identified and replicated a novel region for association on 17q25.1 (Fig. 4a). Two highly correlated variants (rs11655237 and rs7214041, $r^2=0.95$) were associated with pancreatic cancer risk. Variant rs7214041 is to *LINC00673* (long inter-genic non-protein coding RNA 673). rs11655237, a non-coding transcript variant, shows significant DNase hypersensitivity in multiple cancer cell lines and binds transcription factors including *P300*, *FOXA1*, *FOXA2*, and the DNA repair protein *RAD21* according to HaploReg v2¹⁹. HaploRegV2 also indicated rs7214041 alters regulatory motifs for HNF1¹⁹. Interestingly, we also found suggestive evidence of an association with rs7310409 located at the *HNF1A* locus (12q24.31, Supplementary Fig. 3a and Supplementary Table 7). A recent study of the pancreatic cancer transcriptome suggests HNF1A may act as a tumor suppressor in pancreatic cancers²⁰. Variation in *HNF1A* has been associated with risk of Type 2 diabetes^{21,22}, a well-established risk factor for pancreatic cancer^{23–25}, and maturity onset diabetes of the young (*MODY*)²⁶. Furthermore, variants in *HNF1A* (in particular rs7310409) and *HNF4A* were identified as risk factors for pancreatic cancer in pathway-based and candidate-SNP-based analyses of the PanScan data^{27,28}.

We also identified significant association for two variants in high LD (rs9854771 and rs1515496, $r^2=0.99$) located in an intron of *TP63* on 3q29 (Fig. 4b). p63 is a p53 homologue implicated in tumorigenesis and metastasis²⁹ by playing a role in cell-cycle arrest and apoptosis. Overexpression of p63 can mimic p53 activation in certain experimental models³⁰. Interestingly, different isoforms of p63 have opposing effects; TAp63 has tumor suppressive effects while DNp63 has oncogenic effects³¹. Danilov and colleagues suggested DNp63 α was the predominant isoform in pancreatic cancer cell lines and promoted pancreatic cancer growth, motility and invasion³². Previous GWAS studies of lung cancer and bladder cancer have demonstrated significant evidence of association for SNPs in *TP63*^{33–37}. HaploReg query of this region showed that both are predicted to be conserved elements via GERP, suggesting functional roles.

Our analysis revealed genome-wide significance in a region on 2p13.3 (rs1486134). A pancreatic cancer GWAS in Han Chinese subjects¹² found suggestive evidence for another SNP on 2p13.3 (rs2035565) (Supplementary Table 3). High LD is present throughout this region (Fig. 4c), including strong LD between rs1486134 and rs2035565 in European and Asian populations based on 1000 Genomes¹⁵ samples ($r^2=0.91$ and $r^2=0.90$ respectively). This region includes the gene *ETAA1* (Ewing tumor-associated antigen 1), alias *ETAA16*, that may function as a tumor-specific cell surface antigen in the Ewing's family of tumors³⁸.

We observed significant association on 7p13 for rs17688601, located in an intron of the *SUGCT* (succinyl-CoA:glutarate-CoA transferase) gene (alias *c7orf10*) (Fig. 4d). This variant is predicted in HaploREGV2 to alter binding of HNF1-4 and other DNA binding proteins¹⁹. The *SUGCT* protein is involved in glutarate metabolism and mutations in this gene are associated with glutaric aciduria³⁹. While there is evidence of altered tricarboxylic acid cycle metabolism in pancreatic cancer⁴⁰, the role of this gene in pancreatic cancer risk is unclear.

Combined Stage 1 and Stage 2 identified suggestive evidence of association ($P<1\times 10^{-6}$) in four regions: 12q24.31 (*HNF1A*) (Supplementary Fig. 3a), 18q21.2 (*GRP*) (Supplementary Fig. 3b), 1p13.1 (5' of *WNT2B*) (Supplementary Fig. 3c), and 20q13.11 (Supplementary Fig. 3d). *GRP* (gastrin releasing peptide) production has been associated with pancreatic tumor growth in vitro⁴¹. *WNT* signaling plays an important role in pancreas development. *WNT2B* (Wingless-Type MMTV Integration Site Family, Member 2B) is overexpressed in pancreatic cancer and has been associated with decreased survival⁴². The 20q13.11 variant is located ~20kb of the *HNF4A* (*MODY*) gene, mutations of which are associated with early-onset diabetes⁴³.

In the PanC4 study we observed 11 SNPs on chromosome 9q31.3 (Supplementary Fig. 3e) in moderate to high LD (r^2 values between 0.6 and 1) with p-values from 7.00×10^{-8} to 2.73×10^{-6} , including rs10991043 (OR=1.19, 95%CI:1.12–1.26, $P=7.00\times 10^{-8}$) nearby the *SMC2* (structural maintenance of chromosome 2) gene. This gene plays an important role in DNA repair in humans. While there was no evidence of association in the other study populations examined, the strong signal across multiple SNPs in PanC4 suggest that this region merits further investigation.

Further functional characterization of these associated regions is needed, including examining if these SNPs are functional through eQTL. Performing eQTL analysis of pancreatic tissues is challenging. Normal pancreatic tissue is primarily comprised of acinar cells (>90%), but pancreatic ductal adenocarcinoma has a ductal phenotype, and the appropriate normal tissue to analyze is debatable because the cell of origin of pancreatic ductal adenocarcinomas is debated. eQTL analysis of pancreatic tumor tissue is also problematic because the tumor tissue of a pancreatic ductal adenocarcinomas contains a variable mixture of cell types including fibroblasts, multiple types of immune cells, non-neoplastic pancreatic cells and cancer cells, with cancer cells representing only a minority of the total cell population. Furthermore, gene expression analysis of normal pancreatic tissue is often limited by the RNA degradation associated with high level RNAase expression in pancreatic acinar cells. An ideal study of pancreatic eQTLs for pancreatic cells would take into account these challenges.

Smoking is a well-established risk factor for pancreatic cancer⁴⁴⁻⁴⁷. For all nine SNPs identified in Table 1 and Supplementary Table 7, we conducted an analysis stratified by smoking status (ever smoker vs. never smoker) in PanC4 samples. No qualitative differences in effect size between current smokers and never smokers were observed (results not shown). Furthermore, when we included an interaction term in the model, this term was not significant at the 0.05 level.

We estimated the heritability of pancreatic cancer due to common GWAS SNPs using data from PanC4 samples of Caucasian ancestry using only directly genotyped SNPs (3,828 cases, 3,551 controls and 620,357 SNPs) as well as the combined dataset (7,032 cases 6,866 controls 268,681 SNPs). Using a disease prevalence of 0.0149, reflecting the lifetime risk of pancreatic cancer, we estimated that 16.4% (95%CI: 10.4%–22.4%) in PanC4 and 13.1% (95%CI 9.9%–16.3%) for the combined dataset of the total phenotypic variation was explained by genome-wide common SNPs. The established associated regions (loci in Table 1 and Supplemental Table 3), accounted for 3.0% (95%CI: 2.0%-3.9%) and 2.1%(95%CI 1.7%-3.1%) of the total phenotypic variation in the Panc4 population and the combined dataset, respectively.

We identified several novel regions involved in pancreatic cancer susceptibility, and provided additional evidence to support many of the established associations. While it is of interest that many of these highly associated variants are located in the introns of genes, these associations could be due to more distant genomic effects. Follow-up studies, including functional studies, are needed to fully understand how these variants (either directly or indirectly) impact risk of pancreatic cancer. Our work highlights the importance of common variation in pancreatic cancer risk.

Online Methods

Stage 1 Methods

PanC4 Quality Control—In total, 8052 individuals were selected for genotyping from studies participating in the Pancreatic Cancer Case-Control Consortium (PanC4). Participating sites included: The Central Europe study coordinated by the International

Agency for Research on Cancer (IARC/Central Europe)⁴⁸, Johns Hopkins Hospital^{49,50}, Mayo Clinic⁵¹, MD Anderson Cancer Center⁵², Memorial Sloan-Kettering Cancer Center⁵³, University of Toronto⁵⁴, Queensland⁵⁵, University of California San Francisco (UCSF)⁵⁶, and Yale University⁵⁷ (Supplementary Table 1). Cases were defined as individuals with adenocarcinoma of the pancreas. DNA samples from these individuals from PanC4, 180 study duplicates, 176 HapMap control samples, and 26 replicates from the previous pancreatic cancer GWAS PanScan 2¹⁰, were genotyped on the IlluminaHumanOmniExpressExome-8v1 array at the Johns Hopkins Center for Inherited Disease Research (CIDR). Genotypes were called using GenomeStudio version 2011.1, Genotyping Module 1.9.4 and GenTrain version 1.0.

Genotyping results were inspected for quality by assessing the missing call rate, allelic imbalance, heterozygosity, discordance in reported versus genotyped gender, relatedness, ancestry and chromosomal anomalies. Unexpected relatedness between pairs of samples was assessed using the method of moments⁵⁸ implemented in *SNPRelate*⁵⁹. The median genotype call rate was 99.9%, with all individuals having a call rate greater than 98%. After removing individuals with excessive allele sharing, duplicates and subjects with incomplete information on age, 7,956 subjects (4,164 cases and 3,792 controls) were available for statistical analyses (Supplementary Table 2). SNPs with the following characteristics were excluded from statistical analyses: positional duplicates, more than two discordant calls in study duplicates, technical failures or missing call rate greater than 2%, more than one Mendelian error in HapMap control trios, Hardy-Weinberg equilibrium p -value $< 10^{-6}$, sex difference in allele frequency greater than 0.2 for autosomes/XY in samples of European ancestry, and minor allele frequencies (MAF) less than 0.005. Overall 654,470 SNPs passed the quality control filters applied; the median missing call rate was 0.024% and 98% of SNPs had a missing call rate less than 1% (Supplementary Table 2).

PanScan 1 and PanScan 2 Quality Control—PanScan 1 and PanScan 2 data were obtained from dbGAP^{60,61} (dbGaP study accession: phs000206.v4.p3). Data from all participating sites apart from Group Health (which required a separate data sharing agreement) were included in the analysis. Previously published PanScan 1⁹ and PanScan 2¹⁰ studies used the Illumina HumanHap550 and Illumina Human 610-Quad chips respectively. Quality control was performed as described above for PanC4. Forty-five unexpected duplicates between PanScan 1, PanScan 2, and PanC4 were identified and removed from analyses of the PanScan datasets. After data cleaning, 528,179 SNPs and 3,746 individuals (1,856 cases, 1,890 controls) remained in PanScan 1, and 557,555 SNPs and 3,300 individuals (1,618 cases and 1,682 controls) remained in PanScan 2 (See Supplementary Table 4).

Association Analysis—To investigate population structure, principal components analysis (PCA) was conducted separately for PanC4, PanScan 1 and PanScan 2 using *SNPRelate*⁵⁹ (Supplementary Fig. 4). Genotype imputation was performed separately for PanScan 1, PanScan 2 and PanC4 using IMPUTE v2¹⁴. Since PanScan 1 and PanScan 2 SNPs were originally mapped using an older genome assembly (NCBI build 36), we converted their genome position to genome assembly NCBI build 37 by using LIFTOVER.

Markers not identified in the build 37 assembly were removed. To decrease computational time, we pre-phased genotypes to produce best-guess haplotypes using SHAPEIT v2 software⁶². Both 1000 Genomes¹⁵ Phase I-integrated haplotypes (release Dec 2013) and HapMap3¹⁶ (release #2,2009) were used as reference panels during imputation.

After imputation, SNPs with quality scores < 0.3 were excluded from all subsequent analysis. Only SNPs directly genotyped in either PanC4, PanScan 1, or PanScan 2 and passing quality control filters were retained for analysis. This resulted in 866,891 SNPs in the Combined Stage 1 analysis. The expected genotype counts were then analyzed using the frequentist test option of SNPTEST⁶³. Decade of age and eigenvectors from PCA were included as covariates. The number of eigenvectors to include was chosen based on inspection of the scree plot and p-values from association between eigenvectors and pancreatic cancer status. The results from each study were then combined using a fixed-effects inverse standard error approach implemented by METAL¹⁷ (see Supplementary Table 5, column 'Combined Stage 1'). Test statistic inflation (λ), was estimated to be 1.025 for PanC4, 0.998 for PanScan 1, and 1.017 for PanScan 2. Test statistics for PanC4 and PanScan 2 were adjusted to account for small amounts of population stratification using METAL's genomic control option. Our sample size gives us over 80% power to detect an odds ratio of 1.2 for SNPs with a minor allele frequency greater than 0.20. Manhattan and QQ plots of PanC4 GWAS are shown in Fig. 2 and Supplementary Fig. 1, respectively. Manhattan and QQ plots showing association results from the Combined Stage 1 analysis are shown in Fig. 3 and Supplementary Fig. 2. To examine whether our association results were confounded by population stratification, we conducted a secondary analysis, restricting our samples to those of European ancestry based on a PCA analysis performed with PanC4 and Hapmap3 samples. The loci identified through association testing did not change, and their odds ratios and p-values did not vary significantly (results not shown).

Stage 2 Methods

PANDoRA Replication Study—Twenty-five SNPs from 23 independent regions identified as showing evidence of association ($P < 1 \times 10^{-5}$) in either the PanC4 analysis or the Combined Stage 1 analysis, were genotyped in samples from the PANcreatic Disease ReseArch (PANDoRA)¹⁸ consortium with TaqMan technology. These samples were drawn from case-control studies in six European countries: Czech Republic, Germany, Greece, Italy, Lithuania, and Poland. In total, 2497 cases with pancreatic cancer and 4611 controls were genotyped. 8% of samples were duplicated and overall concordance was $>99\%$. Supplementary Table 6 shows the features of the PANDoRA dataset. Samples missing more than 2 SNPs (~15%) or missing covariate information were excluded from analyses. In total, 2,287 cases and 4,205 controls from the PANDoRA study remained after quality control.

Because PANDoRA is a collection of samples from various centers, we analyzed each country separately. Logistic regression models with additive effects of each allele were fit, as implemented in PLINK⁶⁴ (Supplementary Table 5, column 'PANDoRA'). Two SNPs, rs16867971 for Greece and rs10850078 for Lithuania, showed evidence of departure from HWE in controls ($P < 0.001$). The SNP violating HWE was not analyzed for that country. A final fixed-effects meta-analysis of PanC4, PanScan 1, PanScan 2, and PANDoRA

(Combined Stage 1 and 2 analysis) was then conducted using METAL¹⁷ on the 25 SNPs chosen for inclusion in Stage 2. Results are in Supplementary Table 5, column ‘Combined Stage 1&2’. To further interrogate these regions we examined all 1000G imputed SNPs (as described above) in regions with significant or suggestive ($P < 1 \times 10^{-6}$) evidence of association (Fig. 4 and Supplemental Fig. 3).

In our Combined Stage 1 analysis (Supplementary Table 5, column ‘Combined Stage 1’), two SNPs selected for replication were observed to have heterogeneity p-values below 0.001. When restricting our analysis to individuals of European ancestry, heterogeneity p-values from the meta-analysis remained virtually unchanged, implying that the heterogeneity was not due to population stratification. One SNP, rs16867971, was directly genotyped in PanC4 and imputed in PanScan 1 and PanScan 2. We found evidence of association for rs16867971 in PanC4, but not in PanScan 1 or PanScan 2 ($P > 0.05$). The second SNP, rs6706539, was also directly genotyped in PanC4 and imputed in PanScan 1 and PanScan 2. For rs6706539, allele A was associated with increased risk in PanScan 1 and PanScan 2 ($P = 0.008$ and $P = 0.04$, respectively) but protective in PanC4 ($P = 3.4 \times 10^{-6}$). Upon examination of the imputed and non-imputed SNPs adjacent to rs6706539, we found that r^2 values between this SNP and other SNPs within 10kb were low, ranging from 0.05 to 0.18 in 1000 Genomes CEU samples. It is possible that this low LD made imputation of this SNP rather difficult. Additionally, inspection of the alleles coded as reference and alternate alleles for this SNP in PanC4 and 1000 Genomes suggests that this oddity is not due to differences in strand alignment.

Forest plots of our top hits (Supplemental Fig. 5a–5i) showing the magnitude of odds ratios for each study population show that in the majority of the “top” SNPs, those with p-value $< 1 \times 10^{-6}$, the direction of the effect was consistent across populations. Additionally, none of the top SNPs showed significant heterogeneity (at the 0.05 level) in the Combined Stage 1 and Stage 2 analysis. However, in many instances the effect size in the PanScan I population was smaller than the association observed in PanScan II, PanC4 and PANDoRA. We conducted a random effects meta-analysis as well and overall the results were consistent with the results observed from the fixed-effect meta-analysis (results not shown).

Heritability Analysis—Heritability analysis was performed using GCTA⁶⁵ software. This analysis estimates the percentage of phenotypic variance explicated by common SNPs. We assumed a prevalence of 0.0149 (risk to age 90 in the US Caucasian population; SEER data collected in 2009–2011). We excluded individuals not clustering with HapMap¹⁶ CEU (CEPH- Utah residents with ancestry from northern and western Europe) samples in PCA analysis as well as individuals with estimated relationships > 0.05 or missing genotype rate > 0.01 . SNPs with missing rate > 0.05 , MAF < 0.01 and HWE p-value $< 5 \times 10^{-4}$ were also excluded. We estimated the overall heritability in the PanC4 study using SNP data, as well as the heritability attributed to the 12 regions with significant evidence of association in the Caucasian population plus the 6 suggestive regions identified.

HaploReg—HaploReg is a tool used for exploring functional annotations of non-coding variants. For each variant and region identified in this study, we used HaploReg to gain insight into functional annotations including chromatin state (promoters and enhancers),

conserved regions, variant effect on regulatory motifs and protein binding sites. Regions were defined by SNPs with $r^2 > 0.8$ to the associated SNP.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Erica J Childs^{1,54}, Evelina Mocci^{2,54}, Daniele Campa^{3,4,54}, Paige M Bracci⁵, Steven Gallinger⁶, Michael Goggins⁷, Donghui Li⁸, Rachel Neale⁹, Sara H Olson¹⁰, Ghislaine Scelo¹¹, Laufey T Amundadottir¹², William R Bamlet¹³, Maarten F Bijlsma¹⁴, Amanda Blackford², Michael Borges⁷, Paul Brennan¹¹, Hermann Brenner¹⁵, H Bas Bueno-de-Mesquita^{16,17,18,19}, Federico Canzian²⁰, Gabriele Capurso²¹, Giulia M Cavestro²², Kari G Chaffee¹³, Stephen J Chanock¹², Sean P Cleary^{23,24}, Michelle Cotterchio^{25,26}, Lenka Foretova²⁷, Charles Fuchs^{28,29}, Niccola Funel³⁰, Maria Gazouli³¹, Manal Hassan⁸, Joseph M Herman³², Ivana Holcatova³³, Elizabeth A Holly⁵, Robert N Hoover¹², Rayjean J Hung⁶, Vladimir Janout³⁴, Timothy J Key³⁵, Juozas Kupcinskis³⁶, Robert C Kurtz³⁷, Stefano Landi³⁸, Lingeng Lu³⁹, Ewa Malecka-Panas⁴⁰, Andrea Mambrini⁴¹, Beatrice Mohelnikova-Duchonova⁴², John P Neoptolemos⁴³, Ann L Oberg¹³, Irene Orlov¹⁰, Claudio Pasquali⁴⁴, Raffaele Pezzilli⁴⁵, Cosmeri Rizzato²⁰, Amethyst Saldia¹⁰, Aldo Scarpa⁴⁶, Rachael Z Stolzenberg-Solomon⁴⁷, Oliver Strobel⁴⁸, Francesca Tavano⁴⁹, Yogesh K Vashist⁵⁰, Pavel Vodicka⁵¹, Brian M Wolpin^{28,52}, Herbert Yu⁵³, Gloria M Petersen¹³, Harvey A Risch³⁹, and Alison P Klein^{2,7}

Affiliations

¹Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD ²Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD ³Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany ⁴Department of Biology, University of Pisa, Pisa, Italy ⁵Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA ⁶Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada ⁷Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, MD ⁸Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX ⁹Department of Population Health, QIMR Berghofer Medical Research Institute, Queensland, Australia ¹⁰Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY ¹¹International Agency for Research on Cancer (IARC), Lyon, France ¹²Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD ¹³Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN ¹⁴Laboratory for Experimental Oncology and Radiobiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands ¹⁵Division of Clinical Epidemiology and Aging Research, German

Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany ¹⁶Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands ¹⁷Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands ¹⁸Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom ¹⁹Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia ²⁰Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany ²¹Digestive and Liver Disease Unit, “Sapienza” University of Rome, Rome, Italy ²²Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy ²³Department of Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada ²⁴Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada ²⁵Cancer Care Ontario, University of Toronto, Toronto, Ontario, Canada ²⁶Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada ²⁷Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno, Czech Republic ²⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA ²⁹Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA ³⁰Department of Surgery, Unit of Experimental Surgical Pathology, University Hospital of Pisa, Pisa, Italy ³¹Department of Medical Sciences, Laboratory of Biology, School of Medicine, University of Athens, Athens, Greece ³²Department of Radiation Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD ³³Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic ³⁴Department of Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic ³⁵Cancer Epidemiology Unit, University of Oxford, Oxford, U.K ³⁶Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania ³⁷Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY ³⁸Department of Biology, Section of Genetics, University of Pisa, Pisa, Italy ³⁹Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT ⁴⁰Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland ⁴¹Department of Oncology, ASL1 Massa Carrara, Massa Carrara, Italy ⁴²Laboratory of Toxicogenomics, Institute of Public Health, Prague, Czech Republic ⁴³NIHR Pancreas Biomedical Research Unit, Liverpool Clinical Trials Unit and Cancer Research UK CTU Director, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, U.K ⁴⁴Department of Surgery, Gastroenterology and Oncology, University of Padua, Padua, Italy ⁴⁵Pancreas Unit, Department of Digestive Diseases, Sant’Orsola-Malpighi Hospital, Bologna, Italy ⁴⁶ARC-NET: Centre for Applied Research on Cancer, University and Hospital Trust of Verona, Verona, Italy ⁴⁷Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD ⁴⁸Department of

General Surgery, University Hospital Heidelberg, Heidelberg, Germany ⁴⁹Division of Gastroenterology and Research Laboratory, IRCCS Scientific Institute and Regional General Hospital “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy ⁵⁰Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany ⁵¹Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Academy of Sciences, Prague, Czech Republic ⁵²Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA ⁵³Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI

Acknowledgments

This work was supported by RO1 CA 154823. Genotyping Services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to the Johns Hopkins University, contract number HHSN2682011000111.

The IARC/Central Europe study was supported by a grant from the US National Cancer Institute at the National Institutes of Health (R03 CA123546-02) and grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, MH CZ-DRO-MMCI 00209805).

The work at Johns Hopkins University was supported by the NCI Grants P50CA62924 and R01CA97075. Additional support was provided by Susan Wojcicki and Dennis Troper.

The Mayo Clinic Molecular Epidemiology of Pancreatic Cancer study is supported by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701).

The Memorial Sloan Kettering Cancer Center Pancreatic Tumor Registry is supported by P30CA008748, the Geoffrey Beene Foundation, the Arnold and Arlene Goldstein Family Foundation, and the Society of MSKCC.

The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC) (Grant number 442302). RE Neale is supported by a NHMRC Senior Research Fellowship (#1060183).

The UCSF pancreas study was supported by NIH-NCI grants (R01CA1009767, R01CA109767-S1) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the NCI’s SEER Program under contract HHSN261201000140C awarded to CPIC; and the CDC’s National Program of Cancer Registries, under agreement #U58DP003862-01 awarded to the California Department of Public Health.

The Yale (CT) pancreas study is supported by National Cancer Institute at the U.S. National Institutes of Health, grant 5R01CA098870. The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data.

Studies included in PANDoRA were partly funded by: the Czech Science Foundation (No. P301/12/1734), the Internal Grant Agency of the Czech Ministry of Health (IGA NT 13 263); the Baden-Württemberg State Ministry of Research, Science and Arts (Prof. H. Brenner), the Heidelberger EPZ-Pancobank (Prof. M.W. Büchler and team: Prof. T. Hackert, Dr. N. A. Giese, Dr. Ch. Tjaden, E. Soyka, M. Meinhardt; Heidelberger Stiftung Chirurgie and BMBF grant 01GS08114), the BMBH (Prof. P. Schirmacher; BMBF grant 01EY1101), the “5x1000” voluntary contribution of the Italian Government, the Italian Ministry of Health (RC1203GA57, RC1303GA53, RC1303GA54, RC1303GA50), the Italian Association for Research on Cancer (Prof. A. Scarpa; AIRC n. 12182), the Italian Ministry of Research (Prof. A. Scarpa; FIRB - RBAP10AHJB), the Italian FIMP-Ministry of Health (Prof. A. Scarpa; CUP_J33G13000210001), and by the National Institute for Health Research Liverpool Pancreas Biomedical Research Unit, UK. We would like to acknowledge the contribution of Dr Frederike Dijk and Prof. Oliver Busch (Academic Medical Center, Amsterdam, the Netherlands).

Assistance with genotype data quality control was provided by Cecelia Laurie and Cathy Laurie at University of Washington Genetic Analysis Center.

References

1. Ferlay, J., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer; 2013. (online). <http://globocan.iarc.fr>
2. Goggins M, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res.* 1996; 56:5360–4. [PubMed: 8968085]
3. Roberts NJ, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov.* 2012; 2:41–6. [PubMed: 22585167]
4. Jones S, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science.* 2009; 324:217. [PubMed: 19264984]
5. Thompson D, Easton DF, Consortium BCL. Cancer Incidence in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2002; 94:1358–65. [PubMed: 12237281]
6. van Lier MG, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. *Am J Gastroenterol.* 2010; 105:1258–64. author reply 1265. [PubMed: 20051941]
7. Vasen HF, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). *Int J Cancer.* 2000; 87:809–11. [PubMed: 10956390]
8. Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. *Br J Cancer.* 1985; 52:271–3. [PubMed: 4027169]
9. Amundadottir L, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet.* 2009; 41:986–90. [PubMed: 19648918]
10. Petersen GM, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nat Genet.* 2010; 42:224–8. [PubMed: 20101243]
11. Wolpin BM, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet.* 2014; 46:994–1000. [PubMed: 25086665]
12. Wu C, et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. *Nat Genet.* 2012; 44:62–6. [PubMed: 22158540]
13. Low SK, et al. Genome-wide association study of pancreatic cancer in Japanese population. *PLoS One.* 2010; 5:e11824. [PubMed: 20686608]
14. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet.* 2012; 44:955–9. [PubMed: 22820512]
15. Abecasis GR, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491:56–65. [PubMed: 23128226]
16. Altshuler DM, et al. Integrating common and rare genetic variation in diverse human populations. *Nature.* 2010; 467:52–8. [PubMed: 20811451]
17. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010; 26:2190–1. [PubMed: 20616382]
18. Campa D, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Dig Liver Dis.* 2013; 45:95–9. [PubMed: 23206934]
19. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* 2012; 40:D930–4. [PubMed: 22064851]
20. Hoskins JW, et al. Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A. *Carcinogenesis.* 2014

21. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet.* 2010; 42:579–89. [PubMed: 20581827]
22. Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B. The hepatic nuclear factor-1alpha G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. *J Clin Endocrinol Metab.* 1999; 84:1077–82. [PubMed: 10084598]
23. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. *Jama.* 1995; 273:1605–9. [PubMed: 7745774]
24. Li D, et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. *Cancer Causes Control.* 2011; 22:189–97. [PubMed: 21104117]
25. Chari ST, et al. Probability of pancreatic cancer following diabetes: a population-based study. *Gastroenterology.* 2005; 129:504–11. [PubMed: 16083707]
26. Yamagata K, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). *Nature.* 1996; 384:455–8. [PubMed: 8945470]
27. Pierce BL, Ahsan H. Genome-wide “pleiotropy scan” identifies HNF1A region as a novel pancreatic cancer susceptibility locus. *Cancer Res.* 2011; 71:4352–8. [PubMed: 21498636]
28. Li D, et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. *Carcinogenesis.* 2012; 33:1384–90. [PubMed: 22523087]
29. Bergholz J, Xiao ZX. Role of p63 in Development, Tumorigenesis and Cancer Progression. *Cancer Microenviron.* 2012; 5:311–22. [PubMed: 22847008]
30. Flores ER, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. *Cancer Cell.* 2005; 7:363–73. [PubMed: 15837625]
31. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. *Cell Death Differ.* 2011; 18:1487–99. [PubMed: 21760596]
32. Danilov AV, et al. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. *PLoS One.* 2011; 6:e26815. [PubMed: 22053213]
33. Figueroa JD, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. *Hum Mol Genet.* 2014; 23:1387–98. [PubMed: 24163127]
34. Lan Q, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat Genet.* 2012; 44:1330–5. [PubMed: 23143601]
35. Shiraishi K, et al. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. *Nat Genet.* 2012; 44:900–3. [PubMed: 22797724]
36. Miki D, et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. *Nat Genet.* 2010; 42:893–6. [PubMed: 20871597]
37. Rothman N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nat Genet.* 2010; 42:978–84. [PubMed: 20972438]
38. Borowski A, et al. Structure and function of ETAA16: a novel cell surface antigen in Ewing’s tumours. *Cancer Immunol Immunother.* 2006; 55:363–74. [PubMed: 16003559]
39. Marlaire S, Van Schaftingen E, Veiga-da-Cunha M. C7orf10 encodes succinate-hydroxymethylglutarate CoA-transferase, the enzyme that converts glutarate to glutaryl-CoA. *J Inherit Metab Dis.* 2014; 37:13–9. [PubMed: 23893049]
40. Son J, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature.* 2013; 496:101–5. [PubMed: 23535601]
41. Avis I, et al. Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan). *Mol Carcinog.* 1993; 8:214–20. [PubMed: 8280369]
42. Jiang H, et al. Expression of Gli1 and Wnt2B correlates with progression and clinical outcome of pancreatic cancer. *Int J Clin Exp Pathol.* 2014; 7:4531–8. [PubMed: 25120849]
43. Yamagata K, et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). *Nature.* 1996; 384:458–60. [PubMed: 8945471]
44. Fuchs CS, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. *Arch Intern Med.* 1996; 156:2255–60. [PubMed: 8885826]

45. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. *Langenbecks Arch Surg.* 2008; 393:535–45. [PubMed: 18193270]
46. Jang JH, Cotterchio M, Borgida A, Gallinger S, Cleary SP. Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk. *Carcinogenesis.* 2012; 33:818–27. [PubMed: 22301281]
47. Talamini R, et al. Tobacco smoking, alcohol consumption and pancreatic cancer risk: a case-control study in Italy. *Eur J Cancer.* 2010; 46:370–6. [PubMed: 19782561]
48. Urayama KY, et al. Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. *Int J Cancer.* 2011; 129:2875–84. [PubMed: 21520034]
49. Klein AP, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Research.* 2004; 64:2634–2638. [PubMed: 15059921]
50. Brune KA, et al. Importance of Age of Onset in Pancreatic Cancer Kindreds. *Journal of the National Cancer Institute.* 2010; 102:119–126. [PubMed: 20068195]
51. McWilliams RR, et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. *Cancer Res.* 2008; 68:4928–35. [PubMed: 18544627]
52. Hassan MM, et al. Risk factors for pancreatic cancer: case-control study. *Am J Gastroenterol.* 2007; 102:2696–707. [PubMed: 17764494]
53. Olson SH, et al. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. *Cancer Detect Prev.* 2007; 31:345–51. [PubMed: 18031948]
54. Eppel A, Cotterchio M, Gallinger S. Allergies are associated with reduced pancreas cancer risk: A population-based case-control study in Ontario, Canada. *Int J Cancer.* 2007; 121:2241–5. [PubMed: 17582608]
55. Tran B, et al. Association between ultraviolet radiation, skin sun sensitivity and risk of pancreatic cancer. *Cancer Epidemiol.* 2013; 37:886–92. [PubMed: 24075798]
56. Duell EJ, et al. Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:1470–9. [PubMed: 18559563]
57. Risch HA. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. *J Natl Cancer Inst.* 2003; 95:948–60. [PubMed: 12837831]
58. Purcell S, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. *American Journal of Human Genetics.* 2007; 81
59. Zheng X, et al. A high-performance computing toolset for relatedness and principal component analysis of SNP data. *Bioinformatics.* 2012; 28:3326–8. [PubMed: 23060615]
60. Mailman MD, et al. The NCBI dbGaP database of genotypes and phenotypes. *Nat Genet.* 2007; 39:1181–6. [PubMed: 17898773]
61. Tryka KA, et al. NCBI's Database of Genotypes and Phenotypes: dbGaP. *Nucleic Acids Res.* 2014; 42:D975–9. [PubMed: 24297256]
62. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat Methods.* 2013; 10:5–6. [PubMed: 23269371]
63. Marchini J, Howie B. Genotype imputation for genome-wide association studies. *Nat Rev Genet.* 2010; 11:499–511. [PubMed: 20517342]
64. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–75. [PubMed: 17701901]
65. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet.* 2011; 88:294–305. [PubMed: 21376301]




Figure 1.
Overview of Stage 1 and Stage 2 analyses




Figure 2. Manhattan plot of PanC4 association analysis. Loci previously associated with pancreatic cancer in Caucasians are shown in black, 2p13.3 in blue and novel loci in red.





Figure 3. Manhattan plot of Combined Stage 1 association analysis. Loci previously associated with pancreatic cancer in Caucasians are shown in black, 2p13.3 in blue and novel loci in red.




Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Regional association and linkage disequilibrium (LD) plots for four novel genome-wide significant loci: (a) 17q25.1, (b) 3q29, (c) 2p13.3, and (d) 7p13. Association p-values are shown for three analyses: PanC4 only (black circles), Combined Stage 1 (PanC4, PanScan 1, and PanScan 2) (grey circles), and Combined Stage 1 and 2 (PanC4, PanScan 1, PanScan 2, and PANDoRA) (red circles). LD plots are based on 1000 Genomes European samples.

Table 1

Significant ($P < 5 \times 10^{-8}$) association results for pancreatic cancer

Chr ^a SNP Position ^b Gene	Effect Allele (Minor/ Reference Allele)	Statistic	Stage 1				Stage 2	
			PanC4 4,164 cases 3,792 controls	PanScan 1 1,856 cases, 1,890 controls	PanScan 2 1,618 cases and 1,682 controls	Combined Stage 1 ^c 7,638 cases 7,364 controls	PANDoRA 2,497 cases 4,611 controls	Combined Stage 1&2 ^d 9,925 cases 11,569 controls
17q25.1 ^h rs11655237 70,400,166 <i>LINC00673</i>	T/C	maf ^e cases;controls	0.146; 0.110	0.139; 0.129	0.149; 0.116		0.135; 0.114	
		info ^f	0.963	g	g			
		OR (CI) ^g	1.38 (1.26 – 1.52)	1.09 (0.96 – 1.25)	1.34 (1.16 – 1.55)	1.27 (1.19 – 1.36)	1.24 (1.10 – 1.40)	1.26 (1.19 – 1.34)
		p-value	1.38x10 ⁻¹⁰	1.95x10 ⁻¹	2.95x10 ⁻⁴	6.74x10 ⁻¹²	6.40x10 ⁻⁴	1.42x10 ⁻¹⁴
17q25.1 ^h rs7214041 70,401,476 <i>LINC00673</i>	T/C	maf ^e cases;controls	0.148; 0.112	0.140; 0.133	0.150; 0.117		0.139; 0.117	
		info	g	0.966	0.96			
		OR (CI)	1.38 (1.26 – 1.51)	1.07 (0.93 – 1.22)	1.33 (1.15 – 1.53)	1.26 (1.18 – 1.35)	1.25 (1.11 – 1.41)	1.26 (1.19 – 1.34)
		p-value	1.95x10 ⁻¹⁰	3.36x10 ⁻¹	3.69x10 ⁻⁴	2.67x10 ⁻¹¹	3.37x10 ⁻⁴	2.88x10 ⁻¹⁴
2p13.3 rs1486134 67,639,769 <i>ETAA1</i> (2236bp 3')	G/T	maf ^e cases;controls	0.302; 0.275	0.305; 0.292	0.305; 0.276		0.292; 0.273	
		info	g	g	g			
		OR (CI)	1.14 (1.06 – 1.22)	1.06 (0.96 – 1.18)	1.15 (1.03 – 1.28)	1.13 (1.08 – 1.19)	1.16 (1.06 – 1.27)	1.14 (1.09 – 1.19)
		p-value	5.96x10 ⁻⁵	1.57x10 ⁻¹	5.18x10 ⁻³	8.35x10 ⁻⁷	9.42x10 ⁻⁴	3.36x10 ⁻⁹
7p13 rs17688601 40,866,663 <i>SUGCT</i>	A/C	maf ^e cases;controls	0.241; 0.263	0.218; 0.254	0.237; 0.268		0.254; 0.277	
		info	g	g	g			
		OR (CI)	0.89 (0.83 – 0.96)	0.82 (0.73 – 0.91)	0.85 (0.76 – 0.94)	0.87 (0.82 – 0.91)	0.91 (0.83 – 1.00)	0.88 (0.84 – 0.92)
		p-value	1.98x10 ⁻³	1.66x10 ⁻⁴	8.72x10 ⁻³	9.77x10 ⁻⁸	3.93x10 ⁻²	1.41x10 ⁻⁸
3q29 rs9854771 189,508,471 <i>TP63</i>	A/G	maf ^e cases;controls	0.328; 0.362	0.336; 0.366	0.325; 0.356		0.341; 0.356	
		info	g	0.998	0.998			
		OR (CI)	0.86 (0.81 – 0.92)	0.88 (0.80 – 0.90)	0.87 (0.79 – 0.97)	0.87 (0.83 – 0.92)	0.93 (0.86 – 1.01)	0.89 (0.85 – 0.93)
		p-value	3.10x10 ⁻⁵	7.94x10 ⁻³	1.55x10 ⁻²	4.08x10 ⁻⁸	1.01x10 ⁻¹	2.35x10 ⁻⁸

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

^a Cytogenetic regions according to NCBI Human Genome Build 37 and NCBI's Map Viewer

^b SNP position according to NCBI Human Genome Build 37

^c Results from the Combined Stage 1 meta-analysis of PanC4, PanScan 1, and PanScan 2

^d Results from the Combined Stage 1 and 2 meta-analysis of PanC4, PanScan 1, PanScan 2, and PANDORA

^e MAF- minor allele frequency

^f Quality of imputation metric. See online methods for more detail. If snp is genotyped and not imputed, a 'g' is reported

^g Allelic Odds Ratio and corresponding 95% Confidence Interval

^h $R^2 > 0.95$